The first-in-human, open-label, single-dose, exploratory clinical trial evaluating the biodistribution and safety of 203Pb-AR-RMX in patients with somatostatin receptor positive neuroendocrine tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs 203-Pb-AR-RMX (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use; First in man
- 23 Jan 2018 According to an Orano Med media release, AREVA Med changed its name to Orano Med.
- 10 Jul 2017 New trial record
- 22 Jun 2017 According to a RadioMedix media release, this exploratory trial was completed in May 2017.